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E D I T O R I A L
2020 — Year of COVID-19
On the morning of Saturday, 15 February 2020, JTH received a submis-
sion from Dr. Ning Tang and colleagues from Wuhan, China, describing 
a series of patients with coronavirus 19-associated pneumonia in whom 
poor prognostic outcomes were accompanied by abnormal coagulation 
parameters. This study of 183 patients had been completed in just 
5 weeks since the first cases of COVID-19 disease were reported in 
Wuhan. Subsequent to this initial report, a second manuscript was re-
ceived from Dr. Tang and colleagues describing a reduction in mortality 
for patients with severe COVID-19 disease with the use of anticoagu-
lation. These manuscripts have attained the highest Altmetric scores 
ever for JTH publications, and the rest, as they say, is history.
As this editorial is being written in late July, the world has just experienced 
its largest single-day documentation of new COVID-19 cases, 284 196, and 
the total global number of cases stands at 15 636 812. Three countries have 
now recorded more than a million cases of COVID-19, the United States 
(>4 million), Brazil (>2 million), and India (>1 million), and global deaths from 
the disease amount to 636 404. The pandemic continues 7 months after its 
first appearance, and it is unclear whether we are now entering a second 
wave of infection or whether the initial infection has yet to be resolved.
The pandemic has, over the past 7 months, brought about dramatic 
changes to our world in many ways, and many of these changes will 
persist. Aside from the catastrophic health outcomes, many aspects of 
our everyday lives have been affected, and the economic prospects for 
the foreseeable future are desperate. With reference to our restricted 
world of hemostasis and thrombosis, and to the wider community of 
biomedical science, it is also obvious that things will never be the same.
Engagement of the global hemostasis and thrombosis community 
in advancing knowledge relating to COVID-19 has been spectacular. 
Mortality from this disease has two major pathological elements—
deteriorating lung function and thrombosis. Very quickly from early 
work by clinicians like Ning Tang, it was clear that an associated co-
agulopathic state developed in severe cases of COVID-19 and that 
intervention with anticoagulation reduced mortality.
Since these earliest reports, our pathogenic knowledge of the co-
agulopathy has advanced rapidly and shows a complex engagement 
of many aspects of the hemostatic system with abnormal activation of 
platelets, alterations of the fibrinolytic system, and an intense activation 
of the endothelium that possesses the ACE-2 receptor for the SARS-
CoV-2 virus. The persistent endotheliitis that has been documented in 
some cases may well play a critical role in the thrombotic tendency seen 
in these patients who develop both in situ pulmonary and widespread 
micro- and macrovascular thrombotic events that can occur during both 
the acute illness and in the subsequent weeks of convalescence.
In the meantime, many therapeutic interventions have been studied to 
mitigate the profound proinflammatory environment that is present, and 
to reduce the likelihood of thrombosis. Observational studies of anticoag-
ulant interventions have been promising, and we now await the results of 
the many prospective randomized trials that are in progress to determine 
the optimal strategy to reduce the thrombotic burden in this population.
Over the past 6 months, JTH has received >500 submissions relating 
to COVID-19, and our total submission count at the end of June is close to 
our 1-year total in 2019. The rate of collection of COVID-related data and 
generation of reports has been unsurpassed. This change in the rate and 
type of knowledge dissemination has affected not only the conventional 
reporting media such as JTH but also the social media and, increasingly, 
preprint servers such as bioRxiv.org and medRxiv.org, as authors move 
to transmit their new information quicker and to wider audiences. These 
changes have occurred against the preexisting growing interest in open 
access publishing, a principle that continues to gain momentum through-
out the world of scientific publication. There seems little doubt that the 
events of the past 6 months will serve to accelerate the changes in publi-
cation policies that we were already beginning to witness prior to COVID.
So, what of the future, post-COVID? Extraordinary amounts of 
money have been spent by governments during the pandemic to support 
biomedical investigation and innovation and to provide bridge support 
for failing businesses. Enormous deficits will be inevitable in the coming 
years, and there must be a significant concern that funds to maintain 
biomedical science discovery and innovation, and optimal clinical care 
infrastructures will be jeopardized by the spending frenzy of 2020.
In the meantime, the global hemostasis community has con-
tributed brilliantly to the challenge presented by COVID. The wide 
spectrum of responses, from advancement of the basic biological 
understanding of the coagulopathy to therapeutic interventions to 
reduce thrombosis incidence, represents the full potential of the 
community’s collective knowledge and impact.
As we look ahead to the final months of this extraordinary year, 
take care, keep safe, and be kind to one another.
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